Clinical Research Directory
Browse clinical research sites, groups, and studies.
Trial of Tirzepatide for the Treatment of Cannabis Use Disorder
Sponsor: National Institute on Drug Abuse (NIDA)
Summary
The purpose of this randomized, double-blind, placebo-controlled, multi-site clinical trial is to evaluate the safety and efficacy of tirzepatide in a sample of 100 patients diagnosed with moderate or severe CUD by DSM-5 criteria.
Official title: Randomized, Double-Blind, Placebo-Controlled Pilot Trial of Tirzepatide for Treatment of Cannabis Use Disorder (CUD)
Key Details
Gender
All
Age Range
18 Years - 70 Years
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2026-11-15
Completion Date
2028-11-15
Last Updated
2026-03-12
Healthy Volunteers
No
Conditions
Interventions
Tirzepatide
Participants will receive weekly injections of tirzepatide 2.5 mg for 4 weeks. The dose is expected to increase by 2.5 mg every 4 weeks, however, the decision to increase the dose will be made based on the Dose Increase Checklist and shared decision between the site study physician (MD or DO) and the participant.
Placebo
Participants will receive weekly masked injections of placebo.